DATE & TIME
Wednesday, July 15, 2015
5:30 PM – 8:00 PM
5:30 - 6:30 PM Networking Reception (Appetizers/snacks will be provided)
6:30 - 8:00 PM Presentation
Sidley & Austin, DC Office
1501 K Street, NW
Washington, DC 20005
Cross-Industry Business Models and The Value to Your Industry
David Wanetick, CEO, IncreMental Advantage
Whether you are licensing in the life sciences industry or the telecommunications industry, you need to gauge the success that your potential licensees will have in commercializing your inventions. Whether you are a technology transfer professional from academia or from a teaching hospital, you need to be able to determine which of your prospective licensees will be most competitive in their respective sectors.
Wherever your expertise lies in bringing inventions to market, you need to know which collaborations and partnerships you need to avoid on account of their unsustainable business models. A well-drafted license agreement with a partner trapped in a dysfunctional business model is of no value.
This unique session illuminates dozens of warning signs related to problematic business models. Before you enter into your next alliance or license, you should vet your counterpart in terms of issues, such as:
- The Las Vegas Conundrum
- The Icarus Paradox
- Capacity Headfakes
- Business Model Portability
- Market Spoilage
- Technology Overfitting
- Business Model Fragility
- Platform Dependence
- The Free Lunch Paradigm
- Cascading Risks
Special Features: The following topics may be of special interest to life sciences licensing professionals.
- How the funding of research at the National Institutes of Health (NIH) compares with that of the Howard Hughes Medical Institute (HHMI), and how such research funding strategies affect real options value.
- What research published in the British Medical Journal about the suicide patterns of rock stars teaches us about evaluating embryonic companies.
- How the Supreme Court’s decision in the Association for Molecular Pathology v. Myriad Genetics impacts business models.
- How the Munchausen Management Syndrome may duplicitously depress royalty rates and other deal terms.
- The upside of organized crime in terms of inadvertently driving demand for pharmaceuticals.
- The ramifications of market spoilage in patent damages calculations and beyond.
LES Members: $40
Online Registration Deadline: July 10, 2015 12 PM, EST
No refunds after July 10, 2015
Substitutions are permitted
David Wanetick is the CEO of IncreMental Advantage, a world-renowned patent valuation firm. Clients include companies ranging from start-ups to Fortune 100 companies, technology transfer offices, incubators, hedge funds, venture capital firms and private equity players. David developed the Certified Patent Valuation Analyst designation which he has delivered all over the world including the United States, Canada, the United Kingdom, Belgium, Spain, Germany, the Netherlands, Denmark, Israel, Dubai, India, Singapore, Hong Kong, and mainland China. David is the author of the highly-acclaimed, Business Model Validation. Several of David’s articles have appeared in Les Nouvelles.